Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Intermittent versus continuous systemic therapy as treatment for unresectable metastatic colorectal cancer

Información

DOI:
https://doi.org/10.1002/14651858.CD012440Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 21 diciembre 2016see what's new
Tipo:
  1. Intervention
Etapa:
  1. Protocol
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Colorrectal

Copyright:
  1. Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Martine A. Frouws

    Department of Surgery, Leiden University Medical Centre, Leiden, Netherlands

  • Yvette Claassen

    Department of Surgery, Leiden University Medical Centre, Leiden, Netherlands

  • Anne J Breugom

    Department of Surgery, Leiden University Medical Centre, Leiden, Netherlands

  • Esther Bastiaannet

    Correspondencia a: Department of Surgery, Leiden University Medical Centre, Leiden, Netherlands

    [email protected]

  • Simone Mocellin

    Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy

    Istituto Oncologico Veneto, IOV‐IRCCS, Padova, Italy

  • Cornelis JH van de Velde

    Department of Surgery, Leiden University Medical Centre, Leiden, Netherlands

  • Gerrit‐Jan Liefers

    Department of Surgery, Leiden University Medical Centre, Leiden, Netherlands

  • Ellen Kapiteijn

    Department of Medical Oncology, Leiden University Medical Centre, Leiden, Netherlands

Contributions of authors

MF, AB, EB and EK drafted the protocol. All protocol authors read and approved the final draft.

Declarations of interest

EB has no known conflicts of interest.

AJB has no known conflicts of interest.

YC has no known conflicts of interest.

MAF has no known conflicts of interest.

EK has no known conflicts of interest.

GJL has no known conflicts of interest.

SM has no known conflicts of interest.

CJHV has no known conflicts of interest.

Acknowledgements

We thank Dr. Henning Keinke Andersen, Marija Barbateskovic and the members of the Cochrane Colorectal Cancer Group editorial board for their evaluation and advice when writing this protocol.

Version history

Published

Title

Stage

Authors

Version

2016 Dec 21

Intermittent versus continuous systemic therapy as treatment for unresectable metastatic colorectal cancer

Protocol

Martine A. Frouws, Yvette Claassen, Anne J Breugom, Esther Bastiaannet, Simone Mocellin, Cornelis JH van de Velde, Gerrit‐Jan Liefers, Ellen Kapiteijn

https://doi.org/10.1002/14651858.CD012440

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.

Study flow diagram.
Figuras y tablas -
Figure 1

Study flow diagram.

Ir a la figura del protocoloAbrir en una pestaña nueva

Non‐inferiority interpretation of meta‐analysis findings
Figuras y tablas -
Figure 2

Non‐inferiority interpretation of meta‐analysis findings

Ir a la figura del protocoloAbrir en una pestaña nueva

Planned subgroup analysis
Figuras y tablas -
Figure 3

Planned subgroup analysis

Ir a la figura del protocoloAbrir en una pestaña nueva
Table 1. Table 1

Table 1. Examples of intermittent versus continuous treatment schemes

1.

Intermittent: FOLFOX17, 12 weeks; sLV5‐FU22, 24 weeks; FOLFOX7, 12 weeks

Continuous: FOLFOX4 every 2 weeks until progression of disease (PD) (Tournigand 2004)

2.

Intermittent: FOLFIRI3, 12 weeks; chemotherapy‐Free‐Interval (CFI); restart FOLFIRI at PD

Continuous: FOLFIRI, 24 weeks (Alexopoulos 2006)

3.

Intermittent: Bevacizumab + capecitabine/oxaliplatin, 18 weeks; CFI; restart Bevacizumab+ capecitabine/oxaliplatin at PD

Continuous: Bevacizumab + capecitabine/oxaliplatin, 18 weeks; bevacizumab+capecitabine, restart bevacizumab+capecitabine/oxaliplatin at PD (Simkens 2015)

1 FOLFOX: FOL: folinic acid; F: fluorouracil (5‐FU); OX: oxaliplatin.
2 sLV5‐FU2: simplified leucovorin plus bolus and infusional fluorouracil.
3 FOLFIRI: FOL: folinic acid; F: fluorouracil (5‐FU); IRI: irinotecan.

Figuras y tablas -
Table 1. Table 1
Ir a la tabla del protocolo